FDA’s Marks Weighs Ups and Downs of Gene Therapy During Alliance Webinar

Aggressively using all the FDA’s regulatory flexibility to advance burgeoning treatments for rare diseases, particularly gene therapy, was a theme highlighted Monday by CBER Director Peter Marks.
Source: Drug Industry Daily